Abbott Laboratories (NYSE:ABT) is scheduled to announce its second-quarter earnings on Thursday, July 17, 2025. For traders who focus on events, examining the historical reactions of the stock to earnings announcements can offer useful insights.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Abbott (ABT), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
Abbott eyes Q2 growth with strong CGM momentum, cardiac device wins and resilient performance across key segments.
Abbott (ABT) reached $132.02 at the closing of the latest trading day, reflecting a -1.18% change compared to its last close.
Abbott (ABT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abbott debuts FreeStyle Libre 3 Plus in Canada, enhancing diabetes care with the world's smallest glucose sensor.
Abbott Laboratories (NYSE:ABT) has greatly exceeded the broader S&P 500 index this year, with its stock price increasing by 18% compared to the S&P 500's 6% rise. This strong performance is due to the company's solid quarterly results and positive future forecasts.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
In the closing of the recent trading day, Abbott (ABT) stood at $134.11, denoting a -1.58% move from the preceding trading day.
Abbott (ABT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ABT stock surges 21.7% year to date on CGM sales growth and robust diagnostics demand, even as FX and macro risks weigh on forecasts.
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.